1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
3D Global Biotech Inc.

3D Global Biotech Inc.

TTPEX:6808
32.50
TWD
+0.35
(+1.09%)
2.63BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.18
0.23
0.36
0.24
0.2
0.25
0.37
3.86
2.66
- -
Basic EPS, GAAP
-0.71
-0.78
-0.71
-0.88
-1.09
-1.21
-1.03
1.33
0.86
- -
Free Cash Flow per Basic Share
-0.95
-0.65
-0.35
-0.43
-0.71
-0.64
-0.58
0.21
1.35
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.53
- -
Book Value per Share
7.94
7.22
8.94
8.21
7.13
6.03
5.1
11.62
12.79
9.52
Tangible Book Value per Share
4.36
3.7
5.56
5.13
4.34
3.96
3.32
10.49
11.84
8.66
Basic Weighted Avg Shares
51
51
51
54
55
56
56
69
78
77
Sales/Revenue/Turnover
9
12
18
13
11
14
21
266
207
- -
Operating Margin (%)
-448.71
-354.92
-199.73
-379.52
-561.71
-485.87
-304.62
33.39
21.39
- -
Depreciation Expense
5
8
16
24
25
26
23
22
28
- -
Net Income, GAAP
-36
-40
-36
-48
-60
-67
-58
92
67
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
4.55
- -
- -
Profit Margin (%)
-385.89
-335.4
-199.79
-361.35
-539.1
-491.72
-280.87
34.51
32.18
- -
Working Capital
219
186
291
269
225
196
149
783
534
504
LT Debt
- -
- -
- -
17
16
10
4
74
42
38
Total Equity
434
395
489
449
390
341
293
905
985
733
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
13.06
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
14.2
- -
- -
Return on Common Equity (%)
- -
-9.59
-8.22
-10.22
-14.24
-18.37
-18.28
15.31
7.04
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
9
7
7
LT Borrowings
- -
- -
- -
LT Finance Leases
78
42
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
77
77
Market Capitalization
4,258
3,718
2,625

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
851
575
551
Cash, Cash Equivalents & STI
770
477
497
Accounts Receivable, Net
24
72
17
Inventories
38
22
19
Total Current Liabilities
75
41
47
Payables & Accruals
- -
- -
- -
ST Debt
9
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
35.5%
8.82%
Free Cash Flow
- -
102.77%
609.63%
Net Income, GAAP
- -
-52.47%
-27.45%
Sales/Revenue/Turnover
- -
244.69%
-22.19%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
266
2025
- -
- -
207
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.33
2025
- -
- -
0.86
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.53
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Keng Liang Ou
Full Time Employees
43
Sector
Health technology
Industry
Medical specialties
Address
No.99, Xintai 5th Road New Taipei TP Taiwan 221
IPO Date
Dec 25, 2020
Website
3dglobalbiotech.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
3D Global Biotech Inc. (6808.TWO) develops and manufactures medical materials and devices for human tissue and organ reconstruction using 3D bioprinting, cell culture systems, and bio-inks hydrogel technologies. The company offers artificial bone substitutes; skull fixation systems; biological dressings; bio-inks and bioprinting equipment; orthopedic, tooth and jaw, and skull reconstruction products; scalp care products; customized dental medical materials including the SmileAlign transparent correction system and DGRA03 craniofacial jaw reconstruction materials; corneal epithelial reconstruction products; and services for 3D medical image reconstruction, tissue rebuilding, and Class III bio-ink wound healing applications. Founded in December 2014 and headquartered at No. 99, Xintai 5th Road, New Taipei City, Taiwan, it primarily serves medical centers, research institutions, companies, and distributors in the biotechnology sector with a focus on hard and soft tissue reconstruction for domestic and international markets. In June 2024, the company entered a significant patent licensing agreement with major shareholder YD Biopharma, granting exclusive rights to its corneal limbal stem cell technology for an initial USD 1 million fee plus up to USD 4 million in milestones to advance eye disorder treatments. It also maintains a strategic partnership with Japan's WHITE LIGN Inc. for exclusive Taiwan distribution of Smop55 mouth guards and transparent orthodontic systems using WHITE LIGN Dental Sheet materials, expanding into the sports orthodontics market. These alliances enhance its position in personalized high-end medical devices through interdisciplinary collaborations in industry, government, academia, research, and medicine.